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Accepted 3 May 2017; Published online 11 May 2017AbstractThis second article in the series on pragmatic trials describes the challenges in selection of sites for pragmatic clinical trials and the
impact on validity, precision, and generalizability of the results. The selection of sites is an important factor for the successful execution
of a pragmatic trial and impacts the extent to which the results are applicable to future patients in clinical practice. The first step is to define
usual care and understand the heterogeneity of sites, patient demographics, disease prevalence and country choice. Next, specific site char-
acteristics are important to consider such as interest in the objectives of the trial, the level of research experience, availability of resources,
and the expected number of eligible patients. It can be advisable to support the sites with implementing the trial-related activities and mini-
mize the additional burden that the research imposes on routine clinical practice. Health care providers should be involved in an early phase
of protocol development to generate engagement and ensure an appropriate selection of sites with patients who are representative of the
future drug users.  2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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There is growing interest, both from prescribers and
users of new medications, in the generation of evidence
to assess the effectiveness and safety of a drug in a real-
world population. Pragmatic trial design offers the
opportunity to deliver robust data from a representative
population.
Schwartz and Lelouch [1] who first recommended the
use of pragmatic designs acknowledge that most (trials)
contain both explanatory and pragmatic elements. Although
some trials such as the Thrombus Aspiration in
ST-Elevation myocardial infarction in Scandinavia trial, a* Corresponding author. Tel.: þ1-44-7814766147.
E-mail address: sally.d.worsley@gsk.com (S.D. Worsley).
http://dx.doi.org/10.1016/j.jclinepi.2017.05.003
0895-4356/ 2017 The Authors. Published by Elsevier Inc. This is an open acc
licenses/by-nc-nd/4.0/).randomized registry trial [2], can be delivered through a
very pragmatic design, other trials, particularly for pre-
launch drugs, will require the introduction of interventions
through site selection and safety monitoring, which will
result in a trial that can still mostly be pragmatic but does
contain some compromise.
The key elements of trial design are used in the
PRECIS-2 tool [3], which enables the scoring of a trial
across a range from very explanatory to very pragmatic.
The range of potential scores provided by the PRECIS-2
tool is reflective of the multifactorial nature of trial design
and the challenges associated with the delivery of a fully
pragmatic trial.
The GetReal consortium has carried out literature
reviews and extensive interviews with stakeholders. From
this work, a series of articles on pragmatic trials has beeness article under the CC BY-NC-ND license (http://creativecommons.org/
15linical Epidemiology 88 (2017) 14e20What is new?
Key findings
 Successful selection and inclusion of usual care
sites requires prospective analysis of the many var-
iables to be considered when answering the
research question.
What this adds to what was known?
 For pragmatic trials, we have integrated knowledge
on challenges, implications, and potential solutions
for selection and inclusion of usual care sites.
What is the implication and what should change
now?
 Health care providers should be involved
throughout the development of the trial protocol.
This engagement will ensure that the proposed
study design meets their evidence needs and will
also support the appropriate selection of sites.
generated (see Box 1). Site selection was identified as one
of the key factors impacting pragmatic trial success and is
explored in this second article in the series. Aspects to be
considered during site selection include geographical
setting, treatment pathways, site infrastructure, and partici-
pant characteristics. For a pragmatic trial, the provision of
training and ongoing support, where needed, will maximize
the likelihood of a successful outcome. However, a balance
must be struck between many, necessary, design and
operational choices and the impact of these on the applica-
bility of results to the broad patient population receiving
usual care.
S.D. Worsley et al. / Journal of CBox 1 Series on pragmatic trials
Challenges on pragmatic trials: selection and inclu-
sion of usual care sites
Pragmatic trials aim to generate real-world evi-
dence on the relative effects of treatments, generaliz-
able to routine practice. In this series, we will discuss
the interplay between pragmatic trial design, opera-
tional consequences, and the interpretation of results.
1. Introduction: Pragmatic trials and real-world
evidence
2. Selection and inclusion of usual care sites
3. Participant eligibility, recruitment, and retention
4. Challenges of informed consent
5. Questions, comparators, and treatment strategies
6. Outcome selection and measurement
7. Monitoring safety and trial conduct
8. Data collection and management2. The challenges of designing a trial in the usual
care setting
2.1. What is a usual care site?
For a trial to be pragmatic, the research question should
be addressed in the patient’s usual health care setting.
However, agreeing the definition of usual care for an
individual treatment can be challenging. Apart from the
variations in health care that can be encountered in
different geographical locations, patients may simulta-
neously receive care from a mixture of health care
settings, including hospitals, specialist centers, and
primary care. For example, a respiratory patient using
bronchodilators may undergo lung function assessment
at a specialist center while their routine care and prescrip-
tions come from a primary health care setting and phar-
macy. This raises the challenge of ensuring that all
relevant data sources are captured to ensure that data
collected fully represents the patient’s usual care.
In selecting research sites for a pragmatic trial, it is
important to accommodate both the patient’s and physician’s
preference and minimize both the burden for the patient and
the disruption to usual care. For example, a survey of
palliative care health professionals showed that very few
of them were willing to refer their patients with end-stage
disease to studies involving extra tests or hospital visits
[4]. In identifying the routine care setting for a pragmatic
trial, it is not only important to be aware of the location
where the usual care takes place, and where the trial-
related procedures are performed, but also where patients
are most likely to be enrolled.
2.2. Patient population characteristics
The distribution of patient characteristics that influence
treatment effect will differ across sites. This, in turn, may
impact research findings: when sites are highly selected,
the applicability of the results to a more general patient
population may be reduced [5,6]. In an explanatory trial
to assess a treatment for psychotic depression, it was found
that patients with a distinct demography who were added
late into the trial showed a different treatment outcome
from those patients at the original planned sites, rendering
the results statistically insignificant. The authors noted that
increasing the patient sample size, by recruitment from
sites that have patients with different characteristics, does
not necessarily increase power [7].
When there are less strict inclusion criteria, as in a prag-
matic trial, intersite differences reflecting different patient
demographics, clinical characteristics, and treatment pat-
terns may be considerable: severely diseased patients are
usually treated in secondary care, whereas patients with
mild diseases tend to remain in primary care. However,
including a diversity of sites will promote the generaliz-
ability of the research findings to a wide range of patients
who will receive the treatment in the future. The selection
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study sites will be trial specific, and this is an important
area of focus for study teams.2.3. Country setting
The location of pragmatic trial sites may greatly impact
the usefulness of results. It is also a focus of regulatory
discussion. A European Medicines Agency position article
on the applicability of results from trials conducted outside
the European Union (EU) asks for prospective analyses to
determine the relevance of the results to the EU population
[8]. One reason for this is that disease prevalence and nat-
ural history may vary greatly both within a country and
across different countries. For example, the effectiveness
of BCG vaccination has been found to vary between 0%
and 80% with strong correlation with latitude [9]. The effi-
cacy of the vaccine was found to decrease with distance
from the equator, possibly because of greater exposure
nearer to the equator to environmental nontuberculous my-
cobacteria, which may confer protection that mirrors that
conferred by BCG vaccine [10].
Another source of diversity is availability and accessi-
bility of health care, which may lead to a change in the
outcome for the patient. For example, if a required blood
transfusion cannot be performed, this may lead to a fatality
that would not have occurred in a more affluent setting.
Both high- and low-quality health care may alter the
apparent effectiveness of the treatment [5,7,11,12]. An
explanatory trial in 12 European countries to assess the
impact of early surgical intervention found that outcome
for the patient was heavily impacted by their country health
care system, which determined the speed with which they
were treated [13]. Clearly, geographical variations in site
resources can impact the outcome of a pragmatic trial.
Although ideally the full diversity of health care settings
and countries should be reflected in a pragmatic trial, the
choice is often limited by financial, practical, and regulatory
issues. For example, a sponsor may design an effectiveness
trial in specific regions for reimbursement purposes.
Specific countries may be selected based on a greater
recruitment potential and reduced administrative burden
[14e16]. In addition, rigorous regulatory requirements,
predominantly in place for explanatory trials, may not be
feasible for a pragmatic approach. For example, European
Medicines Agency guidance on interventional studies re-
quires frequent reporting of adverse events (AEs) that may
not be necessary or possible in some pragmatic trials.
Clearly, researchers must be aware of the unique ethical
and legal frameworks for each individual country with re-
gard to the conduct of clinical research [15e17]. Combined
with the restrictions on data transfer across country bound-
aries, these challenges may lead to a highly restricted selec-
tion of countries. An early engagement of regional
authorities may facilitate the inclusion of a broader range
of countries, which may yield a more appropriate reflectionof the patient population that will be treated in future clin-
ical practice.2.4. Heterogeneity of selected sites
A heterogeneous selection of sites is often preferable
for a pragmatic trial to ensure that the design includes a
range of settings, clinical patient characteristics, and pa-
tient demography relevant to the research question. The
decision to select homogenous sites (or a single site)
may, however, still be appropriate for some trials, partic-
ularly if strict inclusion and exclusion criteria cannot be
avoided or there is a requirement for a specific diagnostic
test or the trial has complex and non-routine end points.
Often single and/or homogenous centers are sought out
to fulfill a need for specialist expertise or commitment
to a trial design that cannot be replicated in other settings.
One example is the PRIME Malaria trial that was de-
signed to include a relatively homogenous group of public
health centers to accommodate complex fever case man-
agement [18].
However, it is important to be aware that by restricting
the site selection to single and/or homogenous sites, there
is an increased risk that the results from such a trial will
not be applicable to the full diversity of sites and their pa-
tient population [19e21]. A large trial that mostly
comprised surgical patients who were admitted to the inten-
sive care unit (ICU), reported beneficial effects on mortality
after intensive insulin treatment in ICU [22], but this
outcome has not been replicated in two subsequent multi-
center studies that included a broader patient population
admitted to ICU with sepsis [23,24]. In fact, a recent
meta-analysis found no benefit but a significant increase
in the risk of hypoglycemia [25]. Often, even when the pos-
itive outcome can be replicated, the introduction of a more
heterogenous site selection with a broader patient popula-
tion can influence the size and precision of the effect
because of the variations in health care delivery across
sites.
Careful consideration should be given to fully under-
stand the factors that impact the mixture of sites selected.
Even the size and complexity of the hospital can influence
results: in many therapeutic areas, patients often have
better clinical outcomes treated in higher volume
hospitals [19].
The research question dictates the most appropriate
mixture of sites for a pragmatic trial; but this will always
be balanced with the associated operational considerations.3. Selecting sites for a pragmatic trial
Selecting the centers for explanatory trials can be very
straightforward. Decisions can be driven by practical
issues, such as previous experience, success in recruiting
patients, the willingness to participate, and a history of
What is ‘usual care’ in this study?
Have we listened to Physicians, staﬀ and paents when designing the study?
How can we minimise paent burden and addional study-related eﬀorts by site staﬀ?
How can we accommodate paent and physician preference?
Where will paents be seen for usual care, study procedures and enrolment?
How can we ensure diversity of our paent populaon?
Have we considered the impact of disease prevalence and resource availability?
Have we found the opmum balance between diversity of paent populaon, geography, 
heterogeneity of sites, cost implicaons, regulatory consideraons and operaonal limitaons?
How can we opmize the protocol to increase feasibility in roune care seng?
Quesons for Study Teams to considerChallenges
How can we raise awareness about the study and engage Invesgators and site staﬀ?
Have we tailored our awareness acvies to our speciﬁc types of site e.g. Primary care vs. 
Secondary care, GP vs. Specialist?
How can we connect with Healthcare Professional Groups, Paent groups and charies to 
help raise awareness of the study?
How can we best support sites to ensure successful start up/iniaon and minimize me 
to First Subject First Visit e.g. resource, ﬁnancial support for infrastructure?
Can historical data from previous trials support our site feasibility assessment?
Have we determined our site selecon criteria?
Have we determined which paent-level or site-level/healthcare provider characteriscs are 
important for the study and have we got suﬃcient representaveness of these characteriscs?
Have we tailored the site feasibility checklist to our trial and have we asked the right quesons 
to enable us to fully assess a sites capability to run the study? 
Have we got a conngency plan should recruitment of sites be slower than expected?
Does our study speciﬁc training include suﬃcient informaon on the pragmac design and on 
the study objecves, procedures and conduct? 
Is our GCP training content compliant but not overwhelming
Have we chosen the best mode of delivery for training e.g. online, face to face, webinar? 
Trial 
Design
Site
Selecon
Site set-up 
and 
support
Usual Care: Primary care vs. Specialists
Paent Populaon (demographics)
Disease prevalence
Resource Provision
Single country vs. mulnaonal
Study Design: Protocol complexity
Subject Inclusion/Exclusion Criteria
Site experience and training
Research capacity
Representave paent populaon
Capacity for Research
Site Feasibility
Level of training
Engaging invesgators and site staﬀ
Preparing and Supporng Sites
Start up acvies close to centre 
iniaon date
Infrastructure support
Financial consideraons
Pre-launch studies
Fig. 1. The challenges of selection and inclusion of usual care sites for pragmatic trials. A schematic to illustrate the key site features for consid-
eration during each stage of pragmatic trial execution.
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[26]. Pragmatic trial site selection, however, raises many
additional elements that need to be considered in much
greater detail when planning the trial. These are illustrated
in Fig. 1.
3.1. Assessment of feasibility and capacity for research
Sites that are most likely to encounter difficulties in
executing a clinical trial are generally the smaller sites with
limited resources that struggle to deliver trial-related
procedures in addition to usual care [19,27]. A site feasi-
bility checklist is recommended to guide the process of site
readiness, address the feasibility of data collection and the
presence of supporting staff such as a research nurse, and
clarify the expected number of potential participants. Other
important factors that generally facilitate trial execution are
alignment of the protocol with routine clinical practice,
ensuring that the research does not interfere with optimal
care, and minimizing the additional trial-related efforts
for the patient and the hospital staff. The feasibility of
the trial and the alignment with routine care can be opti-
mized by involving physicians and staff early in the proto-
col development phase [28].3.2. Training the site in trial-related procedures
To ensure the quality and validity of data, physicians and
nurses who are new to clinical research may require
training in aspects of trial conduct. They will also need to
complete the International Council for Harmonisation E6
Good Clinical Practice (GCP) qualification. However, the
introduction of GCP training to a research-naive physician
may lessen the degree to which a trial is pragmatic, intro-
ducing requirements for specific monitoring, and may
impact the delivery of usual care.
A further difficulty is that the time-consuming [29]
nature of training may deter physicians from participating
in pragmatic trials [30]. However, the burden of training
can be reduced when using online modules, tailored to
the needs of the trial, as more flexibility can be provided
in the timing and contents of the training. For example,
the TransCelerate Site Qualification and Training Initiative
has developed basic online GCP modules for site personnel.
This has been accepted for GCP qualification by all major
pharmaceutical companies. In addition to completion of
GCP training, site staff will need to be trained on the objec-
tives and procedures of the trial to ensure compliance with
the protocol [31,32].
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Key to the success of trial conduct is the selection of
sites that are supportive of the objectives and willing to
invest the required time and resources. Most usual health
care takes place at primary care sites, and therefore, these
are often the sites of preference for a pragmatic trial. A
number of studies have investigated the attitudes of primary
care physicians to clinical research to better understand
both the potential challenges to participation and the drivers
for active participation [28,30,31,33e38]. In general,
primary care physicians are reported to be supportive of
conducting clinical research. However, from a practical
perspective, many primary care physicians often find it
challenging to dedicate time to participate in research [39].
In two recent pragmatic trials, 59% of sites initially
expressed their interest in trial participation, but less than
4% of the physicians actually recruited participants [30].
As a condition to actively participate, physicians report that
the research must be of scientific interest [30,40], and that
additional time and administrative burden should be mini-
mized, especially during the informed consent phase [36].
Furthermore, the perceived time conflict between providing
care to patients and engaging in a trial can impede partici-
pation [28,41]. Clarifying the added value of the trial for
physicians, patients, and the health care system at an early
stage is important to generate engagement and participa-
tion. general practitioner networks, patient organizations,
and charities can have an important role in this. Asthma
UK and the European Lung Foundation, for instance, raised
awareness for the U-BIOPRED study [42] by providing the
trial objectives on an open access Web site, and this
contributed to the successful recruitment of sites.
3.4. Preparing and supporting sites
When sites are engaged with the research question, it
then follows that trial participation is likely to be high.
Haidich et al. evaluated the enrollment rates in 14 random-
ized trials conducted by the Adult AIDS Clinical Trials
Group and found that sites that had started enrolling
patients soon after site initiation enrolled more than 90%
of the patients [43,44]. This active site engagement may
be developed through close collaboration with sites to facil-
itate timely start-up and recruitment. Financial support for
the implementation of software systems for data capture
or solutions to store files may be considered as an incentive
for small sites with limited resources.4. Particular considerations for a prelaunch prag-
matic trial
To generate data on the riskebenefit profile of a new
medicine in a population with health care systems more
diverse than in an explanatory trial, pharmaceutical com-
panies may plan for a pragmatic trial as part of the drugdevelopment pathway. The design of a prelaunch pragmatic
trial, initiated before the availability of a drug on prescrip-
tion, will face additional challenges.
In addition to the factors that will influence all pragmatic
trials, it will also be necessary to consider the requirements
posed by regulatory authorities, including stringent safety
monitoring and investigational drug supply. One way in
which it is possible to achieve AE reporting is the linkage
of electronic medical records. Linking data from the gen-
eral practitioner, hospitals and pharmacies allow for AE re-
porting with minimal impact to usual care. However, it is
unlikely that an electronic health record (EHR) system will
be set up to routinely capture all data required to support
the objectives of a clinical trial [45]. EHRs do not have
AE fields, so data elements must be identified that are
representative of AEs. This can often require data collec-
tion from several fields or indeed across a number of
EHR systems. Some key data may exist in text notes that
are difficult to use for research [45]. This topic is discussed
further in a later article in this series focused on the chal-
lenges of data collection in pragmatic trials.
For the Salford Lung Study, site selection was confined
to a single region of the United Kingdom [46e48]. This
made it feasible to collect dispensed prescription data from
all the local community pharmacies and to deliver training
in GCP to more than 1,000 nurses, pharmacists, and general
practitioners. However, the convenience and feasibility
provided by a single geographical setting may impact the
applicability of the data to other regions and countries.
Storage for the investigational drug and dispense equipment
in line with GCP may also pose serious challenges resulting
from the need to train and monitor local pharmacies.
The more rigorous requirements of drug provision for a
prelaunch trial may greatly increase the impact of the trial
on usual care and, therefore, the extent to which the trial
can be considered pragmatic. To ease the burden on sites,
the placement of dedicated staff has been shown to be bene-
ficial in trial execution and recruitment [28,45,46]. But
while this increases the potential to deliver robust trial
results through improved operational efficiencies, it may
also impact the degree to which the trial is considered
pragmatic.
The many additional operational challenges associated
with prelaunch pragmatic trials may deter some sponsors
from venturing into this space. But with each new trial,
learnings can be applied to the next, facilitating the execu-
tion of future prelaunch pragmatic trials.5. Conclusions
The pragmatic trial that aims for generalizability to the
target population by broad inclusion criteria, limited impact
on usual care, and selection of a range of sites that reflect the
diversity of sites across countries can also make trial execu-
tion challenging. Successful selection and inclusion of usual
19S.D. Worsley et al. / Journal of Clinical Epidemiology 88 (2017) 14e20care sites requires prospective analysis of the many variables
to be considered to answer the research question. Full trial
feasibility should involve engagement with patients, sites,
and, in the case of prelaunch studies, pharmacies. All these
factors will impact the resources and time required to deliver
what, on the face of it, looks like a very simple trial design.Acknowledgments
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